Revelation Biosciences Inc(REVB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:57 PM ET (Korea 10/31 05:57)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -86.09 | Insider Own | - | Shs Outstand | 0.6M | Perf Week | 6.33% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 44.26% | Insider Trans | - | Shs Float | 0.5M | Perf Month | -28.13% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -6.16 | Inst Own | 7.64% | Short Float | 0.21% | Perf Quarter | -43.56% |
| Income | -0.02B | P/S | - | EPS this Y | 78.35% | Inst Trans | - | Short Ratio | 0.09 | Perf Half Y | -48.6% |
| Sales | 0.00B | P/B | 0.22 | EPS next 5Y | 47.99% | ROA | -120.17% | Short Interest | 0.00M | Perf YTD | -82% |
| Book/sh | 18.03 | P/C | 0.2 | EPS past 3/5Y | 94.09% 76.86% | ROE | -154.77% | 52W High | -90.07% ($40.60) | Perf Year | -88.49% |
| Cash/sh | 20.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -101.25% | 52W Low | 30.84% ($3.08) | Perf 3Y | -99.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 95.51% | Gross Margin | - | Volatility(W/M) | 8.34% 10.85% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.21 | EPS Q/Q | 96.9% | Profit Margin | - | RSI (14) | 39.67 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.21 | Sales Q/Q | - | SMA20 | -8.83% ($4.42) | Beta | -0.15 | Target Price | $124.25 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/8/6 | SMA50 | -30.17% ($5.77) | Rel Volume | 2.12 | Prev Close | $3.75 |
| Employees | 8 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 0.57% - | SMA200 | -50.6% ($8.16) | Avg Volume(3M) | 0.01M | Price | $4.03 |
| IPO | 2020/11/17 | Option/Short | No/Yes | Trades | 211 | Volume | 22,253 | Change | 7.47% |
🧪 Revelation Biosciences () is a clinical-stage biotechnology company headquartered in San Diego, USA, that develops treatments for acute and chronic kidney injury using its "Gemini" platform, which aims to restore balance in immune responses. As a clinical-stage micro-cap biotech company with virtually no revenue, clinical data and capital-raising developments are the key drivers of stock price volatility.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded more than usual. That is 212% of its average volume.
REVB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +78.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.6%.
Tap to view numbers
It ranks #573 of 597 in the industry
Based on market cap of $2M.
HCWB#571 HCW Biologics Inc $2M PER - 
APVO#572 Aptevo Therapeutics Inc $2M PER - REVB#573 Revelation Biosciences Inc $2M PER - 
SLXN#574 Silexion Therapeutics Corp $2M PER - 
ELAB#575 PMGC Holdings Inc $2M PER - 
FAQ
What kind of company is REVB?
REVB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of REVB?
The market cap of REVB is approximately $2M, ranking 5,776 within its sector.
What is the 52-week high and low for REVB?
REVB has recorded a 52-week high of $40.60 and a low of $3.08.
